Novelix Pharmaceuticals (BOM:536565) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:536565 Novelix Pharmaceuticals Ltd BOM:536565
73 GF Score
Price ₹77.97
GF Value ₹144.17
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Novelix Pharmaceuticals Research & Development?

Novelix Pharmaceuticals BOM:536565 -0.80% 73 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:536565 with a GF Score™ of 73/100 and a GF Value™ of ₹144.17 (Possible Value Trap). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Novelix Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Novelix Pharmaceuticals  (BOM:536565) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novelix Pharmaceuticals Research & Development Related Terms

Novelix Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Novelix Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelix Pharmaceuticals Research & Development Chart

Novelix Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novelix Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:536565
73GF Score
Novelix Pharmaceuticals Ltd BOM:536565
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novelix Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Novelix Pharmaceuticals (BOM:536565) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Novelix Pharmaceuticals and its competitors.
Is Novelix Pharmaceuticals' Research & Development too high?
Novelix Pharmaceuticals' current Research & Development is ₹0 Mil. Overall, Novelix Pharmaceuticals has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Research & Development compare to MCK and CAH?
Novelix Pharmaceuticals' Research & Development of ₹0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Novelix Pharmaceuticals and its competitors. Novelix Pharmaceuticals's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹144.17, compared to a current price of ₹77.97 — trading 45.9% below its estimated fair value. The current Research & Development is ₹0 Mil. Novelix Pharmaceuticals' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?

Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued. The current stock price of ₹77.97 is trading 45.9% below its estimated GF Value™ of ₹144.17. GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for BOM:536565:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹144.17 vs. price of ₹77.97 (45.9% below fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novelix Pharmaceuticals Business Description

Address Lingapur LA Builders, Amrutha Estates, 6th floor, House no. 3-6-237/610, Himayath nagar, Hyderabad, TG, IND, 500029
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
73GF Score

Get the complete analysis for BOM:536565

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹77.97
Price
₹144.17
GF Value